Skip to main content

Advertisement

SpringerLink
Log in

Best bang for the buck?

  • Invited Commentary
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2002, 342:145–153.

    Google Scholar 

  2. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004–1010.

    Article  PubMed  CAS  Google Scholar 

  3. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616.

    Article  PubMed  CAS  Google Scholar 

  4. Neal B, MacMahon S, Chapman N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000, 356:1955–1964.

    Article  PubMed  CAS  Google Scholar 

  5. Staessen JA, Wang J, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis Lancet 2001, 358:1305–1315.

    Article  PubMed  CAS  Google Scholar 

  6. Svensson P, Faire U, Sleight P, et al.: Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001, 38:e28-e32.

    PubMed  CAS  Google Scholar 

  7. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033–1041.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Michigan, 3918 Taubman Center, 48109-0356, Ann Arbor, MI, USA

    Alan B. Weder MD

Authors
  1. Alan B. Weder MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weder, A.B. Best bang for the buck?. Current Science Inc 5, 3–5 (2003). https://doi.org/10.1007/s11906-003-0002-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-003-0002-4

Keywords

Search

Navigation